NZCR Biosimilar Success

Participation in clinical trials changes patient’s lives!

Thank you to the 522 New Zealanders who took part in NZCR clinical trials investigating AVT 02.

These trials (completed in 2020) investigated a biosimilar to Humira and led to the registration of this medicine in the European Union recently.

Humira is used to treat inflammatory conditions. The registration of this medicine as an equivalent and cost effective to the currently available Humira will increase access and treatment options for patients suffering with inflammatory conditions all over the world.

NZCR partners with global pharmaceutical and biotechnology companies to research new medicines.